Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,124 across all filing types
Latest filing 2008-08-03 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Distribution Agreement with Clinical Medical Marketing 1
Regulatory Filings Classification · 95% confidence The document is an ASX Company Announcement dated 4 August 2008 regarding a distribution agreement between Sun Biomedical Limited and Clinical Medical Marketing. It details the terms of the agreement, including exclusivity and minimum order quantities for future years. There is no indication that this is a financial report, earnings release, or regulatory filing related to financial results. It is not a report publication announcement since it contains substantive content about a business agreement. The content fits best under a general regulatory announcement category as it does not match any specific financial report or corporate governance filing. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short (2071 characters), and it is a company announcement about a business agreement, not a financial report or management change.
2008-08-03 English
Appendix 4C - quarterly 6 pages ?Kb
Regulatory Filings
2008-07-29 English
Investor Update 4 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is an ASX Company Announcement titled 'Investor Update' dated 28 July 2008. It provides a detailed update on the company's financial performance for the June quarter, including sales revenues and unit sales, as well as a comprehensive description of ongoing capital raising activities via a renounceable Rights Issue. It also includes updates on sales initiatives in various regions, product development, regulatory status, and management/staff changes. The document contains substantive financial data (quarterly sales figures) and detailed operational updates, which go beyond a simple announcement or summary. It is not a full annual report or audit report, nor is it a call transcript or legal proceeding. The focus on quarterly financial performance and operational updates aligns with an Interim / Quarterly Report. The length (8483 characters) and content indicate it is a comprehensive report rather than a brief announcement or presentation. Therefore, the most appropriate classification is Interim / Quarterly Report (IR).
2008-07-27 English
Dispatch of Prospectus 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 15 July 2008 regarding the dispatch of a renounceable Rights Issue Prospectus. It details the terms of the rights issue, including the subscription ratio, price, and underwriting information. The document does not contain financial statements or detailed financial analysis but rather informs shareholders about the rights issue and the dispatch of the prospectus. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is short and it is not a report itself but an announcement related to capital raising.
2008-07-14 English
Expected Date of Quotation of New Shares and Options 1
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Sun Biomedical Limited regarding a change in the expected date of quotation of new shares and options related to a previously issued prospectus. It does not contain financial statements or detailed financial data, nor is it a full report. The content focuses on updating shareholders and the market about the timing of share quotation, which is related to capital market activities. Given the nature of the announcement about share quotation dates and issuance of new shares/options, this fits best under Capital/Financing Update (CAP). The document length is short (1022 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2008-07-01 English
Letter to Shareholders 4 pages ?Kb
Regulatory Filings
2008-07-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.